BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Among 843,208 participants in Israel who were 50 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster. The study period was 54 days; adverse ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-12, Vol.385 (26), p.2413-2420
Hauptverfasser:	Arbel, Ronen, Hammerman, Ariel, Sergienko, Ruslan, Friger, Michael, Peretz, Alon, Netzer, Doron, Yaron, Shlomit
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged BNT162 Vaccine - immunology Chronic illnesses Coronavirus Coronaviruses COVID-19 COVID-19 - mortality COVID-19 - prevention & control COVID-19 vaccines Death Diabetes Drug dosages FDA approval Female Humans Hypertension Immunization Immunization, Secondary Infectious Disease Israel - epidemiology Jewish people Male Middle Aged Mortality Original Proportional Hazards Models Regulatory approval Severe acute respiratory syndrome coronavirus 2 Sociodemographics Software Vaccine Efficacy - statistics & numerical data Vaccines Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among 843,208 participants in Israel who were 50 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster. The study period was 54 days; adverse effects were not recorded.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2115624